Cowen and Company’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cowen and Company’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,800	Closed	-$7K	–	675
2022 Q3	$7K	Buy	+20,800	New	+$519K	﹤0.01%	465

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cowen and Company's AMLX Position: Q4 2022 in Review

Cowen and Company sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2022, closing a stake of 20,800 shares — an estimated $7K sold.

Cowen and Company first reported a position in AMLX in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 133 funds tracked by Wall St. Rank hold AMLX as of Q4 2022.

Cowen and Company reported no remaining Amylyx Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Cowen and Company sold 20,800 Amylyx Pharmaceuticals shares in Q4 2022, an estimated $7K.
Cowen and Company first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Cowen and Company's Amylyx Pharmaceuticals position peaked at $7K in Q3 2022.
133 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.